Literature DB >> 30772277

SLC22A3 is associated with lipoprotein (a) concentration and cardiovascular disease in familial hypercholesterolemia.

Martine Paquette1, Sophie Bernard2, Alexis Baass3.   

Abstract

BACKGROUND AND AIMS: Several clinical and genetic factors have been shown to modulate the cardiovascular risk in subjects affected by familial hypercholesterolemia (FH). Genome wide association studies (GWAS) in the general population have identified several single nucleotide polymorphisms (SNPs) significantly associated with the risk of cardiovascular disease (CVD). This include the rs2048327 variant in the SLC22A3 gene. However, the effect of this SNP in FH subjects is unknown. The objectives of this study are to investigate the association between rs2048327 and the prevalence of CVD as well as with the concentration of lipoprotein (a) (Lp (a)), in a cohort of genetically-confirmed heterozygous FH patients.
METHODS: An enzyme-linked immunoassay kit was used to assess the Lp (a) concentration, whereas an exome chip genotyping method was used to impute the rs2048327 genotype.
RESULTS: The cohort comprised 287 non-carriers (TT), 305 heterozygous carriers (TC) and 76 homozygous carriers of the rs2048327 variant. In a model corrected for traditional cardiovascular risk factors, rs2048327 was significantly associated with Lp (a) level (median value of 12, 16 and 29 mg/dL in TT, TC and CC carriers, respectively, p < .0001). In a model corrected for cardiovascular risk factors and Lp(a) value, carrying the C allele was associated with a 2-fold increased risk of CVD (OR 1.96, 95%CI 1.21-3.19, p = .007).
CONCLUSIONS: In this study, we demonstrated that the rs2048327 SNP of the SLC22A3 gene was significantly associated with Lp(a) as well as with CVD events in FH subjects. Further studies are required in order to investigate the mechanisms behind these associations.
Copyright © 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Familial hypercholesterolemia; Lipoprotein (a); Risk stratification; SLC22A3; rs2048327

Mesh:

Substances:

Year:  2019        PMID: 30772277     DOI: 10.1016/j.clinbiochem.2019.02.008

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  Targeting OCT3 attenuates doxorubicin-induced cardiac injury.

Authors:  Kevin M Huang; Megan Zavorka Thomas; Tarek Magdy; Eric D Eisenmann; Muhammad Erfan Uddin; Duncan F DiGiacomo; Alexander Pan; Markus Keiser; Marcus Otter; Sherry H Xia; Yang Li; Yan Jin; Qiang Fu; Alice A Gibson; Ingrid M Bonilla; Cynthia A Carnes; Kara N Corps; Vincenzo Coppola; Sakima A Smith; Daniel Addison; Anne T Nies; Ralf Bundschuh; Taosheng Chen; Maryam B Lustberg; Joanne Wang; Stefan Oswald; Moray J Campbell; Pearlly S Yan; Sharyn D Baker; Shuiying Hu; Paul W Burridge; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

2.  Polygenic risk modeling with latent trait-related genetic components.

Authors:  Matthew Aguirre; Yosuke Tanigawa; Guhan Ram Venkataraman; Rob Tibshirani; Trevor Hastie; Manuel A Rivas
Journal:  Eur J Hum Genet       Date:  2021-02-08       Impact factor: 5.351

3.  Elevated lipoprotein(a) and genetic polymorphisms in the LPA gene may predict cardiovascular events.

Authors:  Jun-Xu Gu; Juan Huang; Shan-Shan Li; Li-Hua Zhou; Ming Yang; Yang Li; Ai-Min Zhang; Yue Yin; Na Zhang; Mei Jia; Ming Su
Journal:  Sci Rep       Date:  2022-03-04       Impact factor: 4.379

Review 4.  Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.

Authors:  Ahmed Handhle; Adie Viljoen; Anthony S Wierzbicki
Journal:  Vasc Health Risk Manag       Date:  2021-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.